HITS is a South Korean AI drug discovery company founded in 2020 as a KAIST faculty startup by chemistry professor Woo Youn Kim. It develops HyperLab, a web-based AI platform for drug candidate discovery and design covering virtual screening, hit-to-lead design and ADME/T prediction, and commercializes K-Fold, a bio foundation model for protein structure prediction co-developed with KAIST researchers. Its multi-agent AI Co-Scientist, scheduled for full launch in late 2026, supports the research workflow from literature search to data analysis and hypothesis validation, with integration into automated laboratory equipment targeted for 2027.
1
Round
1
Industry
5
Tags
Sep 28, 2026
Latest raise
Funding activity · 1 round
Sep 28, 2026
KRW 18.3B
Series B
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
